AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

KOL Perspectives on BTK Inhibitors in RA, 2018 Study - ResearchAndMarkets.com

February 22, 2019

DUBLIN--(BUSINESS WIRE)--Feb 22, 2019--The “KOL Perspectives: BTK Inhibitors in RA” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.

Questions topics

Key Highlights

Scope

In total, we conducted interviews with 10 KOLs -

KOL data is analyzed to produce -

Reasons to Buy

Key Topics Covered:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/nwftwp/kol_perspectives?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190222005097/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: PROFESSIONAL SERVICES CONSULTING

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/22/2019 03:27 AM/DISC: 02/22/2019 03:27 AM

http://www.businesswire.com/news/home/20190222005097/en